Abdominal aortic aneurysm (AAA) is a local expansion of the abdominal aorta wall caused by a complex multifactorial maladaptive vascular remodeling. Despite recent advances in the management of cardiovascular diseases, there currently is no established drug therapy for AAA. Since the probability of death from a ruptured AAA still remains high, preventive elective repair of AAAs larger than 5.5 cm in luminal diameter is considered the best treatment option. However, perioperative complications are problematic as elective AAA repair comes with numerous intrinsic risks. Impelled by the need of improving AAA therapy, significant efforts have been made to identify pharmacological tools that would slow down AAA enlargement and lower the risk of rupture, thereby reducing the necessity of surgical intervention. In this review, we discuss recent findings addressing molecular targets that could potentially treat AAA, particularly addressing: statins, classical renin angiotensin system (RAS) blockers, the protective arm of RAS, renin inhibitors, tetracyclines, interleukin-1β inhibition, anti-angiogenic agents and urocortins.
Keywords: Abdominal aortic aneurysm, statins, renin angiotensin system, tetracyclines, interleukin-1β.
Medical Therapy of Aortic Aneurysms: A Pathophysiology-Based Approach
Current Vascular Pharmacology Osteoclastogenesis in Abdominal Aortic Aneurysms: A New Therapeutic Target
Current Drug Targets Nanoparticles: A Promising Therapeutic Approach in Atherosclerosis
Current Drug Delivery Screening Aortic Drug Treatments Through Arterial Compliance Measurements
Current Vascular Pharmacology Optimal Time for Pharmacological Treatment of Abdominal Aortic Aneurysm
Current Drug Targets Monocytes, Macrophages and Other Inflammatory Mediators of Abdominal Aortic Aneurysm
Current Pharmaceutical Design The Role of Small, Dense Low-Density-Lipoproteins in Non-Coronary Forms of Atherosclerosis
Vascular Disease Prevention Renal Dysfunction Following Elective Endovascular Aortic Aneurysm Repair
Current Vascular Pharmacology Perioperative Management of Intracranial Aneurysm and Subarachnoid Hemorrhage
Current Pharmaceutical Design Editorial (Hot Toppic:Potential Breakthroughs in the Pharmacological Treatment of Abdominal Aortic Aneurysms)
Current Vascular Pharmacology Anti-epileptic Drug (AED) Use in Subarachnoid Hemorrhage (SAH) and Intracranial Hemorrhage (ICH)
Current Pharmaceutical Design Statins in Aortic Disease
Current Pharmaceutical Design Statin Use in Aortic Aneurismal Disease to Prevent Progression and Cardiovascular Events: Review of Experimental and Clinical Data
Current Vascular Pharmacology Hypoperfusion of the Aortic Wall Secondary to Degeneration of Adventitial Vasa Vasorum Causes Abdominal Aortic Aneurysms
Current Drug Targets Prevention of Intracerebral Haemorrhage
Current Drug Targets Inflammatory Mechanisms in Atherosclerosis: The Impact of Matrix Metalloproteinases
Current Topics in Medicinal Chemistry Abdominal Aortic Aneurysm (AAA): Is There a Role for the Prevention and Therapy Using Antioxidants?
Current Drug Targets Endoplasmic Reticulum Stress in Arterial Smooth Muscle Cells: A Novel Regulator of Vascular Disease
Current Cardiology Reviews Vascular Endothelial Primary Cilia: Mechanosensation and Hypertension
Current Hypertension Reviews Anatomical Approach to Clinical Problems of Popliteal Fossa
Current Rheumatology Reviews